Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lung disease
Biotech
aTyr flunks phase 3 lung disease trial, deflating stock
With a multibillion-dollar market in its sights, the biotech is planning to talk to the FDA about a path forward despite the failure.
Nick Paul Taylor
Sep 15, 2025 9:56am
Wave reports AATD win, but investors lukewarm
Sep 3, 2025 3:00pm
PureTech creates Celea to develop promising lung disease drug
Aug 12, 2025 10:46am
Expedition inks $645M Fosun deal to bring China asset to US
Aug 11, 2025 11:06am
AIRNA preps for clinical test with $155M series B
Apr 1, 2025 7:00am
Boehringer widens fibrosis drug's potential after 2nd ph. 3 win
Feb 10, 2025 10:42am
